

CHECKPOINT TRENDS LIMITED

Formerly known as Rubra Medicaments Limited

Reg. Office: 604, 6th floor, Meghdoot, Gulmohar Cross Road No. 6, JVPD Scheme, Mumbai - 400049

Email ID: rubraltd@gmail.com | **Website:** www.rubramed.com

CIN: L74110MH1991PLC326598 | **Tel:** +91 9167469649

September 6, 2024

To,
BSE Limited,
P.J. Towers, Dalal Street,
Mumbai – 400 001

Scrip Code : **531099**
Sub : **Annual Report of the Company for the FY 2023-24**

Dear Sir / Madam,

In compliance with Regulation 34(1) of the SEBI (LODR) Regulations, 2015, please find attached herewith Annual Report of the Company for the FY 2023-24.

Date of Annual General Meeting - September 30, 2024.

This is for your record and information.

Thanking you,

Yours faithfully,

For **CHECKPOINT TRENDS LIMITED**

Formerly known as Rubra Medicaments Limited



Abha Kapoor
Wholetime and CFO
DIN – 02799429

CHECKPOINT TRENDS LIMITED

Formerly known as Rubra Medicaments Limited

Annual Report 2023 - 24

CONTENTS

PARTICULARS	PAGE NO.
Directors' Report	1
Annexures to Director's Report	11
Form for Disclosure of particulars of contracts/arrangements entered into by the company with related parties referred to in sub section (1) of section 188 of the Companies Act, 2013	12
Details as required under Section 197(12) of the Companies Act, 2013 read with Rule 5(1) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014	14
Corporate Governance	15
NOMINATION AND REMUNERATION POLICY	28
Management Discussion and Analysis	29
Secretarial Audits' Report	31
Statutory Auditors' Report	35
Balance Sheet	46
Statement of Profit and Loss Account	47
Notes to Financial Statements	48
Cash Flow Statement	56

DIRECTORS' REPORT

To,
The Members,
Checkpoint Trends Limited
Formerly known as Rubra Medicaments Limited

Your Directors' have pleasure in presenting Annual Report together with the Audited Accounts of the Company for the year ended 31st March, 2024.

1. FINANCIAL RESULTS

Your Company financial performance during the year 2023-24 is summarized below:

(Rs. In Thousands)

Particulars	2023-2024	2022-2023
Income from Operations	11300	11601.50
Other Income	9.35	16.29
Total Income	11309.35	11617.79
Less: Expenses	(11084.87)	(12424.49)
Profit/(Loss) Before Extraordinary Items and Tax	224.48	(806.70)
Less: Extraordinary Items	-	-
Profit/(Loss) Before Tax	224.48	(806.70)
Less: Taxation	(77.62)	(21.19)
Profit/(Loss) After Tax	302.09	(785.51)
EPS (in Rs.)	0.06	(0.14)

2. FINANCIAL SUMMARY

The Company earned income from operation of Rs. 11309.35 (in thousands) during the FY 2023-24, as compared to the income from operation of Rs. 11617.79 (in thousands) earned in the previous FY 2022-23. The Company's Net Profit for the Financial Year ended March 31, 2024 stood at Rs. 302.09 (in thousands) as against a Net loss of Rs. Rs. 785.51 (in thousands) in the previous year.

3. CHANGE IN NAME OF THE COMPANY

During the financial year under review, there is no change in the name of the Company.

4. CHANGE IN NATURE OF BUSINESS

During the financial year under review, there is no change in the nature of business of the Company.

5. TRANSFER TO RESERVES

No amount has been transferred to Reserves during the year under review.

6. CHANGES IN SHARE CAPITAL

The Authorised Share Capital of the Company is Rs.8,20,00,000/- divided into 82,00,000 equity shares of Rs. 10/- each and the paid-up share capital of the Company is Rs.5,46,83,000/- divided into 54,68,300 equity shares of Rs. 10/- each.

The Company has not issued any kind of shares or securities during the year under review.

7. DIVIDEND

The Board of Directors expressed their inability to recommend any dividend on equity shares for the year ended March 31, 2024.

8. PUBLIC DEPOSITS

During the year, the Company has not accepted any deposits from public nor during the previous financial year.

9. BUY-BACK / SWEAT EQUITY / BONUS SHARES

The Company has neither bought back its shares nor has issued any sweat equity or Bonus shares during the year under review.

10. EMPLOYEES STOCK OPTION PLAN

The Company has not provided any Stock Option Scheme to the Employees.

11. ISSUE OF DEBENTURES, BONDS OR ANY NON-CONVERTIBLE SECURITIES

The Company has not issued any debenture, bonds or non-convertible securities.

12. STATUTORY AUDITORS

The Members had appointed M/s. DD & Company (erstwhile M/s. Dinesh H. Agarwal & Company), Chartered Accountants, as Statutory Auditor of the Company at the Annual General Meeting held on September 29, 2018 and September 30, 2021 for a period of five years in aggregate from FY 2018-19 to FY 2022-2023.

The term of Statutory Auditor will end at the ensuing Annual General Meeting ("AGM") of the Company and the Company is required to appoint new Statutory Auditors.

Pursuant to section 139 of the Companies Act, 2013 the Board in its meeting held on August 30, 2023 has recommended the appointment of M/s. L K Ajmera & Associates Chartered Accountants as new Statutory Auditor of the company to hold office for a period of five (5) financial years (for FY 2023-2024 till FY 2027-2028), i.e from conclusion of this Annual General Meeting till conclusion of Annual General Meeting to be held in the year 2028, at a remuneration to be determined by the Board of Directors and Auditors.

13. INTERNAL AUDITOR

In the Board Meeting held on August 30, 2023, Ms. Ankita Agawane, Internal Auditor of the company had resigned and the Board appointed new Internal Auditor Mr. Arun Mulya for a period of three years from FY 2023-2024 to FY 2025-2026.

14. STATUTORY AUDIT REPORT

The Auditors' Report on the financial statement for the current year is self-explanatory, therefore does not require any further explanation. The Company has already submitted declaration pursuant to Regulation 33(3)(d) of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 to the Stock Exchange(s).

15. COST AUDITOR REPORT AND COST RECORD

Appointment of Cost Auditor and maintenance of cost records is not applicable to the company.

16. SECRETARIAL AUDITOR AND SECRETARIAL AUDIT REPORT

M/s. Maithili Nandedkar & Associates, Practicing Company Secretaries, appointed as Secretarial Auditor in the Board Meeting held on held on August 12, 2021 to conduct the Secretarial Audit for the 3 (Three) financial years FY 2021-22 till FY 2023-24. **Later on, M/s. Maithili Nandedkar & Associates changed their firm name to M/s. MNB & Co. LLP.**

Therefore, M/s. MNB & Co. LLP, Practising Company Secretaries are the secretarial auditor for the financial year 2022-2023 and 2023-2024.

Further, the Board of Directors in their meeting held on May 25, 2024 have re-appointed M/s. MNB & Co. LLP, Practising Company Secretaries for a further period of 3 years i.e. F.Y. 2024-2025 upto F.Y 2026-2027.

The Secretarial Audit Report for the Financial Year 2023-2024 forms part of the Annual Report. The Secretarial Auditors' Report presented to the Members for the year under review is qualified and is annexed to this Report.

The Secretarial Audit report for the current year is self-explanatory, therefore does not require any further explanation and listing fees has not paid due to financial crises faced by the company.

17. DETAILS IN RESPECT OF FRAUDS REPORTED BY AUDITORS UNDER SUB-SECTION (12) OF SECTION 143

There are no frauds reported by the Statutory Auditors of the Company under Section 143 (12).

18. DIRECTORS AND KEY MANAGERIAL PERSONNEL

In accordance with the Companies Act, none of the Directors are liable to retire by rotation at the ensuing Annual General Meeting.

Ms. Komal Behl, Company Secretary, has tendered her resignation effective January 24, 2024. As on date, the Company does not have a Company Secretary.

Ms. Abha Rajesh Kapoor (DIN: 02799429) was re-appointed as Whole-Time Director of the Company for further period of 3 years w.e.f. June 14, 2023 till June 13, 2026

Subsequent to year under review, Mr. Sunil Khandelwal has been ceased to be a Director of the Company due to expiry of his tenure.

Also, Mr. Gopal Kumar Sahu has been re-appointed as Independent Director of the Company for a period of 5 years subject to the approval of the shareholders in the ensuing General Meeting of the Company.

Disclosure Requirement	Details
Name of the Director	Abha Kapoor
Date of appointment	June 14, 2023
Term of Appointment	3 years
Disclosure of relationship between Directors inter-se	Ms. Abha Kapoor is not related to any Director of the Company
Declaration	We confirm that Ms. Abha Kapoor is not debarred from holding the office of Director of the Company, by virtue of any SEBI order or any other such authority.
Names of listed entities in which the person also holds the directorship and the membership of Committees of the board along with listed entities from which the person has resigned in the past three years	Checkpoint Trends Limited
Nature of expertise in specific functional areas	Finance
Brief profile	Ms. Abha Kapor is highly skillful and possesses vast experience in the field of Finance. She is not related to any other Director of the Company and is also not a Director in any other listed company. She or her relatives do not hold any shares in the Company.

Disclosure Requirement	Details
reason for change viz. appointment, re-	Mr. Gopal Kumar Sahu is being re-

appointment, resignation, removal, death or otherwise;	appointed as an Independent Director for second term.
date of appointment/re-appointment /cessation (as applicable) & term of appointment/re-appointment;	Date of re-appointment- With effect from June 11, 2024. His present tenure as Whole-time Director will conclude on June 10, 2024. Terms of Re-Appointment: For the period of five years from the date of appointment subject to shareholders approval.
Names of listed entities in which the person also holds the directorship and the membership of Committees of the board along with listed entities from which the person has resigned in the past three years	Shantee Urban Developers Private Limited- Director
Brief profile (in case of appointment)	Mr. Gopal Sahu is appointed as an Independent Director of the Company. Mr. Gopal Sahu aged 28 years, is a graduate having an experience of over eight years in general trading activities. He is not related to any other Director of the Company and is also not a director in any other listed company. He or his relatives do not hold any shares in the Company.
disclosure of relationships between directors (in case of appointment of a director).	Gopal Sahu is not related to any Director of the Company.

Disclosure Requirement	Details
reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise;	Mr. Sunil Ramesh Khandalwal is ceased to be a director due to expiry of term and not being reappointed.
date of appointment/re-appointment /cessation (as applicable) & term of appointment/re-appointment;	Date of Cessation- With effect from May 27, 2024.
Brief profile (in case of appointment)	Not Applicable
disclosure of relationships between directors (in case of appointment of a director).	Not Applicable

19. ANNUAL RETURN

The Annual Return for the financial year ended March 31, 2024 along with Notice of AGM is being uploaded on the website of the Company. The web link for the same is as under: <https://www.rubramed.com/extract-annual-return.html>

20. DETAILS OF SUBSIDIARIES/ASSOCIATES/JOINT VENTURES, IF ANY:

As on March 31, 2024, the Company does not have any subsidiary, associate or joint venture.

21. CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION & FOREIGN EXCHANGE EARNINGS AND OUTGO

The information pertaining to Conservation of Energy, Technology Absorption and Foreign Exchange earnings and outgo as required under section 134(3)(m) of the Companies Act, 2013 read with rule 8(3) of the Companies (Accounts) Rules, 2014 is annexed to this report as **Annexure II**.

22. VIGIL MEGHANISM

The Company has established a Vigil Mechanism that enables the Directors and Employees to report genuine concerns. The Vigil Mechanism provides for

(a) adequate safeguards against victimization of persons who use the Vigil Mechanism; and

(b) direct access to the Chairperson of the Audit Committee of the Board of Directors of the Company in appropriate or exceptional cases.

The web link for the policy is as under:

<https://www.rubramed.com/policies/Vigil-Mechanism-Policy.pdf>

23. CORPORATE SOCIAL RESPONSIBILITY

The provisions of Corporate Social Responsibility are not applicable to the Company as it does not fall within the purview of Section 135(1) of the Companies Act, 2013.

24. RELATED PARTY TRANSACTIONS

There were no contracts or arrangements entered into by the Company with related parties referred to in sub-section (1) of section 188 of the Companies Act, 2013. The related party transactions as per IND AS 24 are given in the notes to the financial accounts and forms part of the Annual Report.

The policy on Related Party Transactions is part of the website of the Company. The web link for the policy on related party transaction is as under:

<https://www.rubramed.com/policies/Related-Party-Transaction.pdf>

25. RISK MANAGEMENT

The Company has devised and implemented a mechanism for risk management.

26. FAMILIARIZATION PROGRAMME FOR INDEPENDENT DIRECTORS

The Company proactively keeps its Directors informed of the activities of the Company, its management and operations and provides an overall industry perspective as well as issues being faced by the industry. Details of the Familiarization program for Independent Directors form part of the website of the Company. The web link of Familiarization program is as under:

<https://www.rubramed.com/policies/Familiarisation-of-Independent-Director.pdf>

27. MEETING OF BOARD OF DIRECTORS

The details of Board Meeting forms part of Corporate Governance Report.

28. CORPORATE GOVERNANCE

Pursuant to Regulation 15(2) of the Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) 2015, compliance of Corporate Governance is not mandatory. However, the company has complied with the provisions of Regulation 17 to 27 of the Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, to the extent possible. A separate section on Corporate Governance forms part of the Directors' Report as stipulated in Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, is included in the Annual Report as **Annexure V**.

29. MANAGEMENT DISCUSSION AND ANALYSIS REPORT

Management discussion and analysis report is annexed as **Annexure VI**.

30. STATEMENT OF COMPLIANCE OF APPLICABLE SECRETARIAL STANDARDS:

The Board hereby states that the Company has complied with all the applicable secretarial standards to the extent possible.

31. INDEPENDENT DIRECTOR'S MEETING

The Board of Directors of the Company meets once in every Financial Year without the presence of Executive Directors and Management of the Company. The role of the Directors is as per the provisions of Companies Act, 2013 as well as the Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

32. DECLARATION BY INDEPENDENT DIRECTOR

Pursuant to Section 149(6) of the Companies Act, 2013 and SEBI (Listing Obligation and Disclosure Requirement) Regulations, 2015, the Independent Directors of the Company have given the declaration to the Company that they qualify the criteria of independence as required under the Act.

33. BOARD EVALUATION

Pursuant to the provisions of Companies Act, 2013 and SEBI (Listing Obligation and Disclosure Requirement) Regulations, 2015, the Board has carried out annual performance evaluation of its own performance, the directors individually as well the evaluation of the working of its Audit, Nomination & Remuneration and Stakeholder committee, including the Chairman of the Board who were evaluated on parameters such as level of engagement and contribution and independence of judgment thereby safeguarding the interest of the Company. The performance evaluation of the Independent Directors was carried out by the entire Board. The performance evaluation of the Chairman and the Non-Independent Directors was carried out by the

Independent Directors. The Directors expressed their satisfaction with the evaluation process.

34. PARTICULARS OF LOANS GIVEN, GUARANTEES GIVEN OR INVESTMENTS MADE UNDER SECTION 186 OF COMPANIES ACT, 2013

Particulars of loans, guarantees and investments made by Company pursuant to Section 186 of the Companies Act, 2013 are given in the notes to the financial accounts forming part of the Annual Report. The loans and advances made by the Company, during the financial year under review, are within the limits prescribed in the section 186 of the Companies Act, 2013.

35. MATERIAL CHANGES BETWEEN THE DATE OF THE BOARD REPORT AND END OF FINANCIAL YEAR

Subsequent to year under review, there was no change. As per MCA Circular, Current year AGM is being held through Video Conferencing. Necessary procedure is given in the AGM Notice. Members are requested to update their Email ID either by writing to the Company or through the Register or Transfer Agents.

36. MATERIAL DEVELOPMENTS DURING THE FINANCIAL YEAR

Material changes subsequent to the end of the financial year is disclosed herein above.

37. SIGNIFICANT AND / OR MATERIAL ORDERS PASSED BY THE REGULATORS

No significant and/or material order was passed by any Regulator, any Court in India or any Tribunal, impacting the going concern status and the Company's operations in future.

38. THE DETAILS OF APPLICATION MADE OR ANY PROCEEDING PENDING UNDER THE INSOLVENCY AND BANKRUPTCY CODE, 2016 (31 OF 2016) DURING THE YEAR ALONGWITH THEIR STATUS AS AT THE END OF THE FINANCIAL YEAR

As on March 31, 2024, there is no proceeding pending under the Insolvency and Bankruptcy Code, 2016.

39. THE DETAILS OF DIFFERENCE BETWEEN AMOUNT OF THE VALUATION DONE AT THE TIME OF ONE TIME SETTLEMENT AND THE VALUATION DONE WHILE TAKING LOAN FROM THE BANKS OR FINANCIAL INSTITUTIONS ALONG WITH THE REASONS THEREOF

There is no one time settlement done with bank or any financial institution.

40. IN CASE THE SECURITIES ARE SUSPENDED FROM TRADING, THE DIRECTORS REPORT SHALL EXPLAIN THE REASON THEREOF

The trading of the company has not been suspended.

41. NOMINATION AND REMUNERATION POLICY

An extract of the Company's policy relating to directors appointment, payment of remuneration and discharge of their duties is annexed herewith. The web link to the Nomination and Remuneration Policy is as under:

<https://www.rubramed.com/policies/NominationandRemunerationPolicy.pdf>

42. PARTICULARS OF EMPLOYEES AND RELATED DISCLOSURES

The Company does not have any employee/Director who is in receipt of remuneration exceeding the sum prescribed in Section 197 of the Companies Act, 2013 ("the Act") read with Rule 5 of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014.

In terms of the provisions of Section 197(12) of the Act read with Rules 5(2) and 5(3) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, a statement showing the names of the top ten employees in terms of remuneration drawn and names and other particulars of the employees drawing remuneration in excess of the limits set out in the said rules is available for inspection.

Having regard to the second proviso to rule 5(3) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, such particulars shall be made available to any shareholder on a specific request made by him in writing before the date of such Annual General Meeting. Any member interested in obtaining such information may write to the company. The same is annexed herewith as **Annexure- III**.

43. A STATEMENT REGARDING OPINION OF THE BOARD WITH REGARD TO INTEGRITY, EXPERTISE AND EXPERIENCE (INCLUDING THE PROFICIENCY) OF THE INDEPENDENT DIRECTORS APPOINTED DURING THE YEAR

In the opinion of the board, the independent directors fulfill the conditions specified in SEBI (LODR) Regulations, 2015, and are independent of the management of the Company. The Independent Directors have complied with the code prescribed in schedule IV of the Companies Act, 2013.

44. DISCLOSURE UNDER THE SEXUAL HARASSMENT OF WOMEN AT WORKPLACE (PREVENTION, PROHIBITION AND REDRESSAL) ACT, 2013

The company has in place a policy for prevention of sexual harassment in accordance with the requirements of the Sexual Harassment of women at workplace (Prevention, Prohibition & Redressal) Act, 2013. Internal Complaints Committee has been set up to redress complaints received regarding sexual harassment. The Board thereafter constituted a sexual harassment committee where the chairperson of the Committee is Ms. Sneha Thakur, and Ms. Abha Kapoor and Mr. Gopal Sahu are the Members. All employees (permanent, contractual, temporary, trainees) are covered under this policy.

- a. number of complaints filed during the financial year - None
- b. number of complaints disposed of during the financial year - None
- c. number of complaints pending as on end of the financial year – None

45. TRANSFER OF AMOUNTS TO INVESTOR EDUCATION AND PROTECTION FUND

The Company does not have any funds lying unpaid or unclaimed for a period of seven years. Therefore, there were no funds which were required to be transferred to Investor Education and Protection Fund (IEPF).

46. ADEQUACY OF INTERNAL FINANCIAL CONTROLS

The Company has adequate internal financial controls besides timely statutory audit and limited reviews of performance taking place periodically.

47. REGISTRATION WITH INDEPENDENT DIRECTORS DATABANK

The Independent directors of the company are yet to be registered with Independent director databank.

48. DIRECTORS' RESPONSIBILITY STATEMENT

Pursuant to Section 134 of the Act, the Directors state that:

- (a) In the preparation of the annual accounts, the applicable accounting standards have been followed along with proper explanation relating to material departures, if any;
- (b) Appropriate accounting policies have been selected and applied consistently and have made judgments and estimates that are reasonable and prudent, so as to give a true and fair view of the state of affairs of the Company as at March 31, 2024 and of the profit for the Company for the year ended March 31, 2024;
- (c) Proper and sufficient care has been taken for the maintenance of adequate accounting records in accordance with the provisions of the Companies Act, 2013 for safeguarding the assets of the Company and for preventing and detecting fraud and other irregularities;
- (d) The annual accounts have been prepared on a going concern basis;
- (e) Proper internal financial controls were followed by the Company and such internal financial controls are adequate and were operating effectively;
- (f) Proper systems are devised to ensure compliance with the provisions of all applicable laws and that such systems are adequate and operating effectively.

49. ACKNOWLEDGEMENT

Your Directors takes opportunity to show gratitude towards the assistance and co-operation received from Shareholders.

For and on Behalf of the Board of Directors of
Checkpoint Trends Limited
(formerly known as Rubra Medicaments Limited)

Place: Mumbai

Date: September 05, 2024

Abha Kapoor
Whole time Director and CFO
DIN: 02799429

Gopal Kumar Sahu
Director
DIN: 08478039

ANNEXURES TO THE DIRECTOR'S REPORT

Annexure 1 Details of Contracts and Arrangement made with Related Parties in terms of provisions of Section 188 “AOC-2”

Annexure 2 Particulars of energy conservation, technology absorption and foreign exchange earnings and outgo required under the section 134 (3)(m) of the companies act and companies (accounts) rules, 2014

Annexure 3 The information required under Section 197 (12) of the Companies Act, 2013 and the Rule 5 of the Companies (Appointment and remuneration of Managerial personnel) Rules, 2014, in respect of employees of the Company

Annexure 4 Corporate Governance Report

Annexure 5 Management Discussion and Analysis Report

Annexure 6 Secretarial Audit Report in Form MR 3

ANNEXURE I

FORM NO. AOC -2

(Pursuant to clause (h) of sub-section (3) of section 134 of the Act and Rule 8(2) of the Companies (Accounts) Rules, 2014

Form for Disclosure of particulars of contracts/arrangements entered into by the company with related parties referred to in sub section (1) of section 188 of the Companies Act, 2013 including certain arm's length transaction under third proviso thereto.

1. Details of contracts or arrangements or transactions not at Arm's length basis.

SL. No.	Particulars	Details
a)	Name (s) of the related party & nature of relationship	NOT APPLICABLE
b)	Nature of contracts/arrangements/transaction	
c)	Duration of the contracts/arrangements/transaction	
d)	Salient terms of the contracts or arrangements or transaction including the value, if any	
e)	Justification for entering into such contracts or arrangements or transactions'	
f)	Date of approval by the Board	
g)	Amount paid as advances, if any	
h)	Date on which the special resolution was passed in General meeting as required under first proviso to section 188	

2. Details of contracts or arrangements or transactions at Arm's length basis.

Sr. No	Particular	Details
a)	Name (s) of the related party & nature of relationship	Nil
b)	Nature of contracts / arrangements / transaction	-
c)	Duration of the contracts / arrangements / transaction	-
d)	Salient terms of the contracts or arrangements or transaction including the value, if any	-
e)	Date of approval by the Board	-
f)	Amount paid as advances, if any	-

For and on Behalf of the Board of Directors of
Checkpoint Trends Limited
(formerly known as Rubra Medicaments Limited)

Place: Mumbai

Abha Kapoor
Whole time Director and CFO
DIN: 02799429

Gopal Kumar Sahu
Director
DIN: 08478039

Date: September 05, 2024

ANNEXURE II
DETAILS OF CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION AND
FOREIGN EXCHANGE EARNINGS AND OUTGO

A. CONSERVATION OF ENERGY

(a) Major energy conservation measures taken during the year:

The Company has taken adequate measures to conserve energy by continuous monitoring and effective use of energy, which is a continuous process.

(b) Additional investment and proposals, if any, being implemented for reduction of consumption of energy:

No additional investment proposed.

(c) Impact of measures at (a) and (b) above for reduction of energy consumption and consequent impact on the cost of production of goods:

Since it is continuous process of monitoring and usage, the impact is not quantifiable.

(d) During the year company has only consumed electricity as follows:

	2023-24	2022-23
Total Electricity Expenses	NIL	NIL

B. TECHNOLOGY ABSORPTION

Particulars with respect to technology absorption are given below:

a. Research and Development (R & D)

i. Specific areas in which R & D carried out by the Company:

The Company has not carried out any research and development activities during the year under review.

ii. Benefits derived as a result of the above R & D : Not Applicable

iii. Future plan of Action : NIL

iv. Expenditure on R & D.: NIL

b. Technology absorption, adoption and innovations: NIL

C. FOREIGN EXCHANGE EARNINGS AND OUTGO: NIL

For and on Behalf of the Board of Directors of
Checkpoint Trends Limited
(formerly known as Rubra Medicaments Limited)

Place: Mumbai

Date: September 05, 2024

Abha Kapoor
Whole time Director and CFO
DIN: 02799429

Gopal Kumar Sahu
Director
DIN: 08478039

ANNEXURE- III

Details as required under Section 197(12) of the Companies Act, 2013 read with Rule 5(1) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014

- a) **The percentage increase in remuneration of each Director, Chief Financial Officer, Company Secretary and Whole Time Director during the financial year 2023-24, ratio of the remuneration of each Director to the median remuneration of the employees of the Company for the financial year 2023-24 are as under:**

Sr. No.	Name of Director/KMP and designation	Remuneration of Director/KMP for Financial Year 2023-24 (Rs. in Lakhs)	% increase/ (decrease) in Remuneration for Financial Year 2023-24	Ratio of remuneration of each Director to median remuneration of employees
-	-	-	-	-

- b) **Percentage increase in the median remuneration of employees in the financial year**

In the financial year 2023-24, there was no increase in the median remuneration of employees.

- c) **Number of permanent employees on the rolls of Company**

There are 5 permanent employees on the rolls of Company as on March 31, 2024.

- d) **Average percentile increase already made in the salaries of employees other than the managerial personnel in the last financial year and its comparison with the percentile increase in the managerial remuneration and justification thereof and point out if there are any exceptional circumstances for increase in the managerial remuneration:**

There has been no increase in the salaries of employees and the managerial personnel for the financial year i.e. 2023-24.

For and on Behalf of the Board of Directors of
Checkpoint Trends Limited
(formerly known as Rubra Medicaments Limited)

Place: Mumbai
Date: September 05, 2024

Abha Kapoor
Whole time Director and CFO
DIN: 02799429

Gopal Kumar Sahu
Director
DIN: 08478039

ANNEXURE IV

CORPORATE GOVERNANCE

COMPANY'S PHILOSOPHY ON CORPORATE GOVERNANCE

The Company firmly believes that Corporate Governance and compliance practices are of paramount importance in order to maintain the trust and confidence of the stakeholders, clients, and the good reputation of the Company and the unquestioned integrity of all personnel involved with the Company.

Pursuant to Regulation 15(2) of the Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) 2015, compliance of Corporate Governance is not mandatory. However, the company has complied with the provisions of Regulation 17 to 27 of the Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, to the extent possible.

The Company's philosophy on Corporate Governance envisages the attainment of highest levels of transparency, accountability and equity, in all facets of its operations and in all interactions with its stakeholders, including shareholders, employees, the government and lenders.

BOARD OF DIRECTORS

The Board of Directors along with its Committees provides leadership and vision to the management and supervises the functioning of the Company. In terms of the Company's Corporate Governance Policy, all statutory and other significant and material information are placed before Board to enable it to discharge its responsibilities of strategic supervision of the Company as trustees of stakeholders.

Details of Composition of Board as on March 31, 2024 are given below:-

Sr. No.	Name of the Director	Category	Date of Appointment	Directorship in Other Companies#	Membership of Committee*	Member as Chairman of Committee
1.	Ms. Abha Kapoor	Whole time Director	14/06/2016	1	0	0
2.	Ms. Sneha Thakur	Non-Executive – Independent Director	07/07/2017	0	3	3
3.	Mr. Sunil Khandalwal	Managing Director	28/05/2018	0	0	0
4.	Mr. Gopal Sahu	Non-Executive – Independent Director	11/06/2019	1	3	0
5.	Mr. Harish Surve	Non-Executive –	15/04/2021	0	3	0

		Independent Director				
--	--	-------------------------	--	--	--	--

Ms. Abha Rajesh Kapoor (DIN: 02799429) was re-appointed as Whole-Time Director of the Company for further period of 3 years w.e.f. June 13, 2023 to June 12, 2025.

Subsequent to year under review, Mr. Sunil Khandalwal, has been ceased as Managing Director of the Company due to the expiry of tenure and not being reappointed.

Subsequent to year under review, Gopal Sahu has been re-appointed as Independent Director of the Company for a period of 5 years, subject to the approval of the Shareholders of the Company.

#Includes Private Companies but excludes Limited Liability Partnership, Foreign Companies, Section 8 Companies & Alternate Directorship

*includes Audit Committee and Stakeholders Relationship Committee only, of all companies including this company

None of the Directors of the Company are directors in any other listed Company

Note: None of the Director is a member of more than 10 committees or acting as Chairman of more than 5 committees across all companies in which he is a director.

During the financial year 2023-24, six (06) Board Meetings were held i.e. on May 26, 2023, August 11, 2023, August 30, 2023, September 30, 2023, November 07, 2023 and February 07, 2024.

ATTENDANCE OF DIRECTORS FOR THE YEAR 2023-24

Name of Director	Board Meeting	Audit Committee	Nomination and Remuneration Committee	Stakeholders Relationship Committee	AGM
Ms. Abha Kapoor	6 of 6	-	-	-	Yes
Mr. Sunil Khandalwal	1 of 6	-	-	-	Yes
Ms. Sneha Thakur	6 of 6	6 of 6	2 of 2	4 of 4	Yes
Mr. Gopal Sahu	6 of 6	6 of 6	2 of 2	4 of 4	Yes
Mr. Harish Surve	6 of 6	6 of 6	2 of 2	4 of 4	Yes

DISCLOSURE OF RELATIONSHIP BETWEEN DIRECTORS INTER-SE

None of the Directors of the Company are related to each other. None of the Directors hold any share in the Company.

NUMBER OF SHARES AND CONVERTIBLE INSTRUMENTS HELD BY NON- EXECUTIVE DIRECTORS;

None of the Directors/KMP holds any shares in the Company

CHART OF SKILLS/EXPERTISE/COMPETENCE OF THE BOARD OF DIRECTORS:

The following are the skills/competencies determined as required for the discharge of the obligations by the Board:

Major Classification	Sub Classification	Remarks
Industry Related	Specific Skills	Good knowledge about the trading business and industry and the issues specific to the Company.
	Technical Skills	Technical/professional skills and specialist knowledge about the Company, its market, process, operations, etc. (For Executive Directors).
Strategy & Policy	Strategy	Ability to identify and critically assess strategic opportunities and threats to the business. Guiding development of strategies to achieve the overall goals.
	Policies	Guidance for development of policies and other parameters within which the Company should operate for better control and management.
	Crisis Management	Ability to guide crisis management and provide leadership in hours of need.
Risk & Compliance	Operational	Identification of risks related to each area of operation.
	Legal	Monitor the risks and compliances and knowledge of regulatory requirements.
	Financial	Experience in accounting and finance, ability to analyze the financial statements presented, assess the viability of various financial proposals, oversea funding arrangements and budgets.

INDEPENDENT DIRECTORS

In the opinion of the board, the independent directors fulfill the conditions specified in SEBI (LODR) Regulations, 2015, and are independent of the management of the Company.

AUDIT COMMITTEE

The terms of reference of the Audit committee include the matters specified under SEBI (Listing Obligation and Disclosure Requirement) Regulations, 2015 as well as in Section 177 of the Companies Act, 2013. The terms of reference of the Audit Committee, *inter alia*, include the following:

- oversight of the listed entity's financial reporting process and the disclosure of its financial information to ensure that the financial statement is correct, sufficient and credible;
- recommendation for appointment, remuneration and terms of appointment of auditors of the listed entity;
- approval of payment to statutory auditors for any other services rendered by the statutory auditors;
- reviewing, with the management, the annual financial statements and auditor's report thereon before submission to the board for approval, with particular reference to:
 - a. matters required to be included in the director's responsibility statement to be included in the board's report in terms of clause (c) of sub-section (3) of Section 134 of the Companies Act, 2013;
 - b. changes, if any, in accounting policies and practices and reasons for the same;
 - c. major accounting entries involving estimates based on the exercise of judgment by management;
 - d. significant adjustments made in the financial statements arising out of audit findings;
 - e. compliance with listing and other legal requirements relating to financial statements;
 - f. disclosure of any related party transactions;
 - g. modified opinion(s) in the draft audit report;
- reviewing, with the management, the quarterly financial statements before submission to the board for approval;
- reviewing, with the management, the statement of uses / application of funds raised through an issue (public issue, rights issue, preferential issue, etc.), the statement of funds utilized for purposes other than those stated in the offer document / prospectus / notice and the report submitted by the monitoring agency, monitoring the utilization of proceeds of a public or rights issue, and making appropriate recommendations to the board to take up steps in this matter;
- reviewing and monitoring the auditor's independence, performance, and effectiveness of audit process;
- approval or any subsequent modification of transactions of the listed entity with related parties;
- scrutiny of inter-corporate loans and investments;
- valuation of undertakings or assets of the listed entity, wherever it is necessary;
- evaluation of internal financial controls and risk management systems;
- reviewing, with the management, performance of statutory and internal auditors, adequacy of the internal control systems;
- reviewing the adequacy of internal audit function, if any, including the structure of the internal audit department, staffing and seniority of the official heading the department, reporting structure coverage and frequency of internal audit;
- discussion with internal auditors of any significant findings and follow up there on;
- reviewing the findings of any internal investigations by the internal auditors into matters where there is suspected fraud or irregularity or a failure of internal control systems of a material nature and reporting the matter to the board;
- discussion with statutory auditors before the audit commences, about the nature and scope of audit as well as post-audit discussion to ascertain any area of concern;
- to look into the reasons for substantial defaults in the payment to the depositors, debenture holders, shareholders (in case of non-payment of declared dividends) and creditors;
- to review the functioning of the whistle blower mechanism;

- approval of appointment of chief financial officer after assessing the qualifications, experience and background, etc. of the candidate;
- Carrying out any other function as is mentioned in the terms of reference of the audit committee.

The Audit Committee met six (6) times during the year ended March 31, 2024, i.e. on May 26, 2023, August 11, 2023, August 30, 2023, September 28, 2023, November 07, 2023 and February 07, 2024.

The Composition of Audit Committee after year ended March 31, 2024 is as under:

Name of the Member	Status
Ms. Sneha Thakur	Chairperson
Mr. Gopal Sahu	Member
Mr. Harish Surve	Member

NOMINATION AND REMUNERATION COMMITTEE

a) Brief description of terms of reference

1. formulation of the criteria for determining qualifications, positive attributes and independence of a director and recommend to the board of directors a policy relating to, the remuneration of the directors, key managerial personnel and other employees;
2. formulation of criteria for evaluation of performance of independent directors and the board of directors;
3. devising a policy on diversity of board of directors;
4. identifying persons who are qualified to become directors and who may be appointed in senior management in accordance with the criteria laid down, and recommend to the board of directors their appointment and removal.
5. Whether to extend or continue the term of appointment of the independent director, on the basis of the report of performance evaluation of independent directors.

The Nomination & Remuneration Committee met two (2) times during the year ended March 31, 2024 i.e., May 26, 2023 and February 07, 2023.

Composition

The Composition of Nomination and Remuneration after year ended March 31, 2023 is as under:

Name of the Member	Status
Ms. Sneha Thakur	Chairperson
Mr. GopalSahu	Member
Mr. Harish Surve	Member

STAKEHOLDERS RELATIONSHIP COMMITTEE

- a. The Committee looks into issues relating to shareholders / investors, including complaints relating to transfer / transmission of shares, issue of duplicate share certificates, non-receipt of annual report etc. and their redressal.

- b. The Composition of Stakeholders Relationship Committee after year ended March 31, 2024 is as under:

Name of the Member	Status
Ms. Sneha Thakur	Chairperson
Mr. Gopal Sahu	Member
Mr. Harish Surve	Member

- c. The Board has delegated power of approving transfer of shares to RTA.
d. The Company Secretary of the Company is the Compliance Officer.
e. During the year under review, no complaints were received from Shareholders / Investors.

The Stakeholder Relationship Committee met four (4) time during the year ended March 31, 2024, i.e. on May 26, 2023, August 11, 2023, November 07, 2023 and February 07, 2024.

GENERAL BODY MEETINGS

The details of Annual General Meetings (AGM) of the Company held in last 3 years are as under:

AGM	Date	Time	Venue
2020-21	30/09/2021	10 a.m.	Registered Office
2021-22	30/09/2022	11 a.m.	Registered Office
2022-23	30/09/2023	10 a.m.	Registered Office

Director attended the last Annual General Meeting.

Details of special resolution passed in last three Annual General Meetings:

Sr. No	Particulars	Date
1.	Reappointment Of Mr. Sunil Khandalwal (DIN: 07803085) as Managing Director	30.09.2021
2.	Appointment Of Mr. Harish Surve (DIN: 09138943) as an Independent Director	30.09.2021
3.	Re-appointment of Ms. Sneha Thakur as Non-executive Independent Director	30.09.2022
4.	Reappointment Of Ms. Abha Kapoor (Din: 02799429) As Whole-Time Director	30.09.2023

Details of Special Resolutions passed through postal ballot during the previous Financial Year 2021-2022:

During the year under review, members have approved change of name of the company from Rubra Medicaments Limited to Checkpoint Trends Limited and also added new object to the its main object, in the postal ballot dated April 6, 2022.

Procedure adopted for postal ballot:

In accordance with General Circular Nos. 14/2020 dated April 8, 2020 and 17/2020 dated April 13, 2020 read with other relevant circulars, including General Circular No. 10/2021 dated June 23, 2021, issued by the Ministry of Corporate Affairs (“MCA Circulars”), above mentioned resolution was proposed to be passed by means of Postal Ballot, only by way of remote e-voting process (“e-voting”).

In compliance with Regulation 44 of the SEBI LODR and pursuant to the provisions of Sections 108 and 110 of the Act read with the rules framed thereunder and the MCA Circulars, the manner of voting on the proposed resolution is restricted only to e-voting i.e., by casting votes electronically instead of submitting postal ballot forms. In compliance with the MCA Circulars, the postal ballot notice and instructions for e-voting are being sent only through electronic mode to those Members whose email addresses are registered with the Company / depository participant(s).

M/s. Maithili Nandedkar & Associates, Practising Company Secretaries, acted as Scrutinizer for conducting the Postal Ballot in a fair and transparent manner.

Members exercised their vote(s) by e-voting during the period from Saturday March 5, 2022 at 10.00 a.m. and ended on Monday, April 4, 2022 at 5.00 p.m.

The Scrutinizer submitted their report on April 6, 2022, after the completion of scrutiny and result of the e-voting was announced on the same day. The summary of voting result is given below:

1. To approve change in name of the Company

Particulars	% of total votes	Result
Votes in favour of the Resolution	100%	Passed with Requisite Majority
Votes against the Resolution	0%	

2. To addition to Main Object of the company

Particulars	% of total votes	Result
Votes in favour of the Resolution	100%	Passed with Requisite Majority
Votes against the Resolution	0%	

MEANS OF COMMUNICATION

Your Company regularly provides relevant information to the Stock Exchange as per the requirements of the provisions of the SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015.

- The quarterly, half-yearly and Annual financial results of the Company are published in leading newspapers in India and uploaded with BSE Limited.

- The results and official news are available on www.bseindia.com and the website of the Company www.rubramed.com
- Your Company has posted all its Official News releases on its website.
- No formal representations were made to Institutional Investors or Analysts during the year under review.

GENERAL SHAREHOLDER INFORMATION

Detailed information in this regard is provided in section “Shareholders Information” which forms part of this Annual Report.

a. Annual General Meeting

Day & Date: September 30, 2024

Venue: Registered Office

Time: 10:00 a.m.

Financial Calendar: 1st April, 2023 to 31st March, 2024

b. Financial year April 1, 2023 – March 31, 2024 Calendar (tentative dates of declaration of Quarterly results)

1st Quarter: Within 45 Days from end of respective quarter

2nd Quarter: Within 45 Days from end of respective quarter

3rd Quarter: Within 45 Days from end of respective quarter

4th Quarter: Within 60 Days from end of respective quarter

c. **Date of Book Closure** : September 24, 2024 till September 26, 2024. (Both days inclusive).

d. **Dividend Payment** : NIL

e. **Listing of Shares** : Bombay Stock Exchange Limited

P.J. Towers, Dalal Street, Mumbai – 400 001

f. **Listing Fees** : The Company is in process of paying the Listing Fees And depository fees for the financial year 2023-24

g. **Stock Code** : 531099

h. **Demat ISIN No. in NSDL & CDSL** : INE396H01019

i. **Market Price Data** :

Month	Price on BSE (Rs.)			
	Open	High	Low	Close
Apr 2023	4.65	4.95	4.65	4.95
May 2023	5.19	5.19	4.94	4.94
June 2023	4.94	4.94	3.76	4.73
July 2023	4.96	5.46	4.5	5.2
Aug 2023	5.2	5.2	5.2	5.2
Sept 2023	5	5	4.52	4.52

Oct 2023	4.3	5.06	4.09	4.64
Nov 2023	4.87	8.83	4.42	8.83
Dec 2023	9.27	12.39	8.25	8.57
Jan 2024	8.73	10.36	7.75	9.88
Feb 2024	4.65	4.95	4.65	4.95
Mar 2024	5.19	5.19	4.94	4.94

j. BSE Sensex

Month	Open	High	Low	Close
Apr-23	59131.16	61209.46	58793.08	61112.44
May-23	61301.61	63036.12	61002.17	62622.24
Jun-23	62736.47	64768.58	62359.14	64718.56
Jul-23	64836.16	67619.17	64836.16	66527.67
Aug-23	66532.98	66658.12	64723.63	64831.41
Sep-23	64855.51	67927.23	64818.37	65828.41
Oct-23	65813.42	66592.16	63092.98	63874.93
Nov-23	63829.87	67069.89	63550.46	66988.44
Dec-23	67181.15	72484.34	67149.07	72240.26
Jan-24	72218.39	73427.59	70001.6	71752.11
Feb-24	71998.78	73413.93	70809.84	72500.3
Mar-24	72606.31	74245.17	71674.42	73651.35

k. Distribution of Holding as on March 31, 2024

Shareholding of Nominal Value	Shareholders	%	Shares	%
Upto 5,000	1373	68.1390	2194790	4.0137
5,001 – 10,000	275	13.6476	2378180	4.3490
10,001 – 20,000	130	6.4516	2111700	3.8617
20,001 – 30,000	51	2.5310	1319740	2.4134
30,001 – 40,000	21	1.0422	732990	1.3404
40,001 – 50,000	46	2.2829	2210910	4.0431
50,001 – 1,00,000	56	2.7792	4278680	7.8245
1,00,001 and above	63	3.1266	39456010	72.1541
TOTAL	2015	100	54683000	100

l. Shareholding Pattern as on March 31, 2024

Categories	No. of Shares	% of Shareholding
Bodies Corporate	394177	7.21
Clearing Members	6200	0.11
N.R.I.	56750	1.04
Public	5011173	91.64

Total	54,68,300	100.00
--------------	------------------	---------------

m. Registrar and Transfer Agent

Bigshare Services Pvt Ltd

G-10, Left Wing, Amruta Ville, OppYashoda Hospital, Raj Bhavan Road, Somajiguda, Hyderabad, Telangana - 500082, Andhra Pradesh;

Tel.:040-23374967; **Fax:** 23370295;

Email: bsshyd1@bigshareonline.com ; **Website:** www.bigshareonline.com

n. Share Transfer System: Share Transfer in physical form are generally registered and returned within 15 days from the date of receipt in case if documents are complete in all respects.

o. Outstanding GDRs/ADRs/Warrants or any convertible instruments, conversion data likely impact on Equity: NIL

p. Dematerialization of shares and liquidity: 78.08% of the shares are held in DEMAT form. Company has DEMAT connectivity with CDSL & NSDL.

Bifurcations of shares held in physical and demat form as on 31st March, 2024.

Particulars	No. of Shares	%
Physical Segment	11,98,600	21.92
Demat Segment		
NSDL	18,78,104	34.34
CDSL	23,91,596	43.74
Total	54,68,300	100.00

q. Nomination

Individual Shareholders holding shares singly or jointly in physical form can nominate a person in whose name the shares shall be transferable in case of death of the registered shareholder(s). Nomination facility in respect of shares held in electronic form is also available with the depository participants as per the bye-laws and business rules applicable to NSDL and CDSL. Nomination forms can be obtained from your Company's Registrar and Share Transfer Agent.

r. Address for Communication

Registered Office* : 604, 6th floor, Meghdoot, Gulmohar Cross Road No. 6, JVPD Scheme, Mumbai 400049

Mobile No: +91 9167469649; Email ID: rubraltd@gmail.com

s. Credit Ratings: The Company has not obtained any credit rating for its securities.

s. Other Disclosures:

(i.) Disclosures on materially significant related party transactions:

The Company does not have any materially significant related party transactions, which may have potential conflict with the interest of the Company.

(ii.) Cases of Non-compliances / Penalties: None

- (iii.) Vigil Mechanism / Whistle Blower: Information relating to Vigil mechanism has been provided in the Board's Report. The Company has adopted the Whistle Blower Policy with direct access to Chairman of Audit Committee. The policy is available on the website of the company.
- (iv.) Details of compliance with mandatory requirements and adoption of the non-mandatory requirements: The Company has complied with all mandatory and applicable requirements. However there has been delay in LODR Compliance
The Company has complied with all mandatory and applicable requirements
- (v.) Policy for determining material subsidiaries: The Company does not have any subsidiary. Hence, the Company does not require formulating Policy for determining material subsidiaries
- (vi.) Policy on dealing with Related Party Transactions: Policy on dealing with Related Party Transactions is disseminated on the website of the company:
<http://www.rubramed.com/policies/Related-Party-Transaction.pdf>
- (vii.) Commodity Price Risk or Foreign Exchange Risk and Hedging Activities: The Company has not undertaken any Foreign Exchange or hedging activities.
- (viii.) Details of utilization of funds raised through preferential allotment or qualified institutions placement as specified under Regulation 32 (7A): Not applicable
- (ix.) Certificate from a company secretary in practice that none of the directors on the board of the company have been debarred or disqualified from being appointed or continuing as directors: Not applicable
- (x.) Recommendations of the Committee which were not accepted by the Board of Directors: None
- (xi.) Total fees for all services paid by the listed entity and its subsidiaries, on a consolidated basis, to the statutory auditor and all entities in the network firm/network entity of which the statutory auditor is a part:
There were no payments to the Statutory Auditor or other entities in the network firm/network entity of which the statutory auditor is a part by the Company, other than the audit fee and related payments as disclosed in the financial statements.
- (xii.) Disclosures in relation to the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013 –
 - a. number of complaints filed during the financial year - NIL
 - b. number of complaints disposed of during the financial year - NIL
 - c. number of complaints pending as on end of the financial year - NIL
- (xiii.) The Register of Contracts/ Statement of related party transactions are placed before the Board/ Audit Committee regularly.
- (xiv.) None of the shares of the Company are held by the non-executive Directors of the Company.
- (xv.) There were no pecuniary transactions of the Non-executive Directors viz-a-viz the Company.
- (xvi.) The Auditors has given an unmodified opinion on the financial statement.
- (xvii.) Internal Audit Report is placed before the Audit committee.

CODE OF CONDUCT

The Company's Board of Directors has adopted the code of conduct which governs the conduct of all Directors / Employees. All Directors and senior management personnel have affirmed compliance with respective codes for the year ended on March 31, 2024. The Declaration by Board of Directors to this effect is reproduced below.

CEO/CFO CERTIFICATION

A certificate signed by CFO is attached with this report.

DECLARATION

It is hereby declared that all the Board Members and Senior Managerial Personnel have affirmed compliance of code of conduct, pursuant to Corporate Governance, for the year ended 31st March 2024.

For and on Behalf of the Board of Directors of
Checkpoint Trends Limited
(formerly known as Rubra Medicaments Limited)

Place: Mumbai

Date: September 05, 2024

Abha Kapoor
Whole time Director and CFO
DIN: 02799429

Gopal Kumar Sahu
Director
DIN: 08478039

CHIEF FINANCIAL OFFICER (CFO) CERTIFICATION

To
The Board of Directors,
Checkpoint Trends Limited
Formerly known as Rubra Medicaments Limited

I, Chief Financial Officer of the Company, do hereby certify that:

1. I have reviewed the financial statements and the cash flow statement for the year 2023-24 and to the best of our knowledge and belief:
 - a. These statements do not contain any materially untrue statement or omit any material fact or contain statements that might be misleading.
 - b. These statements present a true and fair view of the Company's affair and are in compliance with existing accounting standards, applicable laws and regulations.
2. There are, to the best of my knowledge and belief, no transactions entered into by the Company during the year which are fraudulent, illegal or in violation of the Company's Code of Conduct.
3. We accept responsibility for establishing and maintaining internal controls for financial reporting and that we have evaluated the effectiveness of internal control systems of the Company pertaining to financial reporting and we have disclosed to the auditors and the Audit Committee, deficiencies in the design or operation of such internal controls, if any, of which we are aware and the steps we have taken or propose to take to rectify these deficiencies.
4. We have indicated to the auditors and the Audit committee:
 - a. Significant changes in internal control over financial reporting during the year;
 - b. Significant changes in accounting policies during the year and that the same have been disclosed in the notes to the financial statements; and
 - c. Instances of significant fraud of which we have become aware and the involvement therein, if any, of the management or an employee having a significant role in the Company's internal control system over financial reporting.

For and on Behalf of the Board of Directors of
Checkpoint Trends Limited
(Formerly known as Rubra Medicaments Limited)

Sd/-
Abha Kapoor
Director (Finance) & CFO
DIN: 02799429

Date: September 05, 2024
Place: Mumbai

NOMINATION AND REMUNERATION POLICY

Extract of the Policy is as under:

Appointment of Directors:

The appointments of Directors are recommended by the Nomination and Remuneration Committee of the Company however all the appointments are subject to approval of Board of Directors of the Company.

Remuneration to Directors and Key Managerial Personnel:

None of the directors are entitled to any Remuneration or any sitting fees however reimbursement of expenses is allowed wherever expense is made for the Company.

The Company Secretary of the Company is entitled to fixed remuneration which is fixed by the Managing Director of the Company.

Discharge of Duties:

Directors and KMP are required to perform all the duties which are mentioned under the Articles and all other duties as may be prescribed by the Board of Directors of the Company.

The web link of the Nomination and Remuneration policy is as under:

<https://www.rubramed.com/policies/NominationandRemunerationPolicy.pdf>

For and on Behalf of the Board of Directors of
Checkpoint Trends Limited
(formerly known as Rubra Medicaments Limited)

Place: Mumbai

Date: September 05, 2024

Abha Kapoor
Whole time Director and CFO
DIN: 02799429

Gopal Kumar Sahu
Director
DIN: 08478039

ANNEXURE- V

MANAGEMENT DISCUSSION AND ANALYSIS REPORT

The Company is into the business of trading. The key issues of the Management Discussion and Analysis are given hereunder:

Industry Structure and Development

The recent global economic situation has witnessed immense highs and lows including some unfortunate happenings. Timing is the most important factor while trading. This fluctuates on rapid basis. According to experts most of the time markets have overvalued or undervalued. With the help of Indian market today one need to test one's financial knowledge, analytical capabilities, thought process and mental strength.

Discussion on financial performance with respect to operational performance

As mentioned earlier in the report that the company as a strategy is currently not pursuing any manufacturing business.

Segment-wise or product-wise performance

The Company is into single reportable segment only.

Outlook

Rubra Medicaments Limited remains confident of the long-term growth prospects & opportunities ahead of it in its business.

Internal control system and adequacy

The system of internal control has been established to provide reasonable assurance of safeguarding assets, maintenance of proper accounting records in compliance with applicable Laws and Regulations to ensure reliability of financial statements and reports. The Statutory Auditors and the Audit Committee review all financial statements and ensure adequacy of internal control systems.

Opportunities and Threats

The strength of a company is known from sound advices. It also depends on the Government policies of taxation. Introduction of GST may give a big boost to the market.

Risks Management

Risk evaluation and management of risk is an ongoing process in the company.

Human Resources

Since your Company is in the trading industry, the criticality of talented man-power and their retention needs no emphasis. Your company is in the process of working out a comprehensive plan to attract, motivate and retain highly skilled and technically competent man-power.

Details of Significant Changes

- Debtors Turnover	:	1.99
- Inventory Turnover	:	Nil
- Interest Coverage Ratio	:	Nil
- Current Ratio	:	2.14
- Debt Equity Ratio	:	Nil
- Operating Profit Margin	:	1.99
- Net Profit/Loss Margin	:	2.67

Details of change in Return on Net Worth as compared to immediately previous financial year along with the detailed explanation thereof

-Return on networkth
FY 2021-22: (0.67) %
FY 2022-23: (1.44) %
FY 2023-24: 5.67%

Cautionary Statement

Statements in the Management discussion and analysis describing the company's objectives, projections, estimates and expectations may be "forward looking statements" within the meaning of applicable laws and regulations. Actual results could differ materially from those expressed or implied. Important factors that could make a difference to the company's operations include economic conditions affecting demand/supply and prices, conditions in the domestic and overseas markets in which the company operates/ going to operate, changes in government regulations, tax laws and other statutes and other incidental factors.

For and on Behalf of the Board of Directors of
Checkpoint Trends Limited
(formerly known as Rubra Medicaments Limited)

Place: Mumbai

Date: September 05, 2024

Abha Kapoor
Whole time Director and CFO
DIN: 02799429

Gopal Kumar Sahu
Director
DIN: 08478039

ANNEXURE- VI

SECRETARIAL AUDIT REPORT
Form No. MR-3

For the financial year ended on March 31, 2024
[Pursuant to Section 204(1) of the Companies Act, 2013 and Rule No. 9 of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014]

To,
The Members,
CHECKPOINT TRENDS LIMITED
(Formerly known as Rubra Medicaments Limited)
604, 6th floor, Meghdoot, Gulmohar
Cross Road No. 6, JVPD Scheme,
Mumbai 400049, Maharashtra, India.

CIN: L74110MH1991PLC326598

We have conducted the Secretarial Audit of the compliance of applicable statutory provisions and the adherence to good corporate practices by **CHECKPOINT TRENDS LIMITED** (hereinafter called the Company) for the Financial Year ended 31st March, 2024. Secretarial Audit was conducted in a manner that provided us a reasonable basis for evaluating the corporate conducts/statutory compliances and expressing our opinion thereon.

Based on our verification of the Company's books, papers, minute books, forms and returns filed and other records maintained by the Company and also the information provided by the Company, its officers, agents and authorized representatives during the conduct of Secretarial Audit, we hereby report that in our opinion, the Company has, during the audit period covering the financial year ended on **March 31, 2024** complied with the statutory provisions listed hereunder and also that the Company has Board-processes and compliance-mechanism in place to the extent, in the manner and subject to the reporting made hereinafter.

We have examined the books, papers, minute books, forms and returns filed and other records maintained by the Company for the financial year ended on March 31, 2024 according to the provisions of:

- (i) The Companies Act, 2013 (the Act) and the Rules made there under;
- (ii) The Securities Contracts (Regulation) Act, 1956 ('SCRA') and the Rules made there under: -
(to the extent applicable during the period under review)
- (iii) The Depositories Act, 1996 and the Regulations and Bye-Laws framed there under; (to the extent applicable during the period under review)
- (iv) Foreign Exchange Management Act, 1999 and the Rules and Regulations made there under to the extent of Foreign Direct Investment, Overseas Direct Investment and External Commercial Borrowings; (to the extent applicable during the period under review)
- (v) The following Regulations and Guidelines prescribed under the Securities and Exchange Board of India Act, 1992 ('SEBI Act'):
 - (a) The Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 (to the extent applicable during the period under review);
 - (b) The Securities and Exchange Board of India (Share Based Employee Benefits and Sweat Equity) Regulations, 2021; (to the extent applicable during the period under review);

- (c) The Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015; *(to the extent applicable during the period under review)*;
 - (d) The Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018 *(to the extent applicable during the period under review)*;
 - (e) The Securities and Exchange Board of India (Employee Stock Option Scheme and Employee Stock Purchase Scheme) Guidelines, 1999; *(to the extent applicable during the period under review)*;
 - (f) The Securities and Exchange Board of India (Issue and Listing of Debt Securities) Regulations, 2008 and The Securities and Exchange Board of India (Issue and Listing of Non-Convertible Securities) Regulations, 2021; *(to the extent applicable during the period under review)*;
 - (g) The Securities and Exchange Board of India (Registrars to an Issue and Share Transfer Agents) Regulations, 1993 regarding the Companies Act and dealing with client; *(to the extent applicable during the period under review)*
 - (h) The Securities and Exchange Board of India (Delisting of Equity Shares) Regulations, 2021 *(not applicable during the period under review)*;
 - (i) The Securities and Exchange Board of India (Buyback of Securities) Regulations, 2018 *(to the extent applicable during the period under review)*;
 - (j) The Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 *(to the extent applicable during the period under review)*
- (vi) We have relied on the representations made by the Company and its officers for systems and mechanism formed by the Company for compliances under other applicable Acts, Laws and Regulations to the Company.

As per management representation received to us stating that during audit period, the Company has adequate and proper compliance mechanism system in place for compliance of laws applicable, as mentioned herein below:

- Labour laws and other incidental laws related to wages, gratuity, provident fund, Employees State Insurance Corporation, compensation, etc.
- Direct and indirect taxes.
- Electricity Act, Environment protection related acts, Explosives act, Motor vehicle Act, Energy Conservation related acts, Indian Boilers related act, Fire prevention and life safety related acts
- Factories Act, 1948 along with local factories Act and rules
- Industrial Disputes Act,
- Legal Metrology Act

We have also examined compliance with the applicable Clauses of the following:

- (i) The Company has complied with Secretarial Standards pursuant to Section 118(10) of the Companies Act, 2013 with regard to Members Meeting and Board of Directors Meetings.
- (ii) Listing Agreements entered into by the Company with BSE Limited.

We further report that:

The Board of Directors of the Company is duly constituted with proper balance of Executive Directors, Non-Executive Directors and Independent Directors. The changes in the composition of the Board of Directors that took place during the period under review were carried out in compliance with the provisions of the Act.

During the year under consideration, following are changes in Board of Directors and Key Managerial personnel:

1. Re-appointment of Ms. Abha Kapoor as Whole Time Director for further period of 3 years through approval of members at the Annual General Meeting held on 30th September, 2023.

Adequate notice is given to all the Directors to schedule the Board Meetings and detailed notes on agenda were sent well in advance or with due consents for shorter notice from the Directors and adequate system exists for seeking and obtaining further information and clarifications on the agenda items for meaningful participation at the meeting.

Majority decision is carried through while the dissenting members' views are captured and recorded as part of the minutes.

We further report that no event occurred during the audit period having a major bearing on the affairs of the Company in pursuance of the above referred laws, rules, regulations, guidelines, standards, etc. except the following:

1. *Ms. Komal Behl, Company Secretary, has tendered her resignation effective January 24, 2024. As on date, the Company does not have a Company Secretary.*
2. *None of the Independent Directors of the Company are empaneled in Independent Director's Databank.*
3. *The company had delayed in payment of listing fees to Stock Exchange as per Regulation 14 of SEBI (Listing Obligation and Disclosures Requirement), 2015.*
4. *The Company had delayed in payment of fees to Depository Participants (CDSL and NSDL).*

We further report that:

There are adequate systems and processes in the Company commensurate with the size and operations of the Company to monitor and ensure compliance with applicable Laws, Rules, Regulations and guidelines.

For MNB & Co. LLP
Practicing Company Secretaries

CS Maithili Nandedkar
Partner
FCS: 8242, C P No. 9307
UDIN: F008242F000447065
Peer Reviewed Firm No. 1259/2021

Place: Mumbai
Date: May 25, 2024

Note: This report is to be read with our letter of even date which is annexed as Annexure herewith and forms and integral part of this report.

ANNEXURE TO SECRETARIAL AUDIT REPORT

To,
The Members,
CHECKPOINT TRENDS LIMITED
(Formerly known as Rubra Medicaments Limited)
604, 6th floor, Meghdoot, Gulmohar
Cross Road No. 6, JVPD Scheme,
Mumbai 400049, Maharashtra, India.
CIN: L74110MH1991PLC326598

Our report of even date is to be read along with this letter.

1. Maintenance of secretarial records is the responsibility of the management of the Company. Our responsibility is to express an opinion on these secretarial records based on our audit.
2. We have followed the audit practices and processes as were appropriate to obtain reasonable assurance about the correctness of the contents of the secretarial records. The verification was done on test check basis to ensure that correct facts are reflected in secretarial records. We believe that the processes and practices, we followed provide a reasonable basis for our opinion.
3. We have not verified the correctness and appropriateness of financial records and Books of Accounts of the Company.
4. Wherever required, we have obtained the Management representations about the compliance of Laws, Rules and Regulations and happening of events etc.
5. The compliance of the provisions of corporate and other applicable Laws, Rules, Regulations and Standards is the responsibility of management. Our examination was limited to the verification of procedures on test basis.
6. The Secretarial Audit report is neither an assurance as to the future viability of the Company nor of the efficacy or effectiveness with which the management has conducted the affairs of the Company.

For MNB & Co. LLP
Company Secretaries

CS Maithili Nandedkar
Partner
FCS: 8242, CP No. 9307

Place: Mumbai
Date: May 25, 2024

**INDEPENDENT AUDITORS' REPORT FOR THE FINANCIAL YEAR ENDED ON
31/03/2024**

To
The Members of
M/s Befound Movement Limited
(Formerly known as Regency Trust Limited)
Mumbai

Report on the Audit of Financial Statements Opinion

We have audited the financial statements of **BEFOUND MOVEMENT LIMITED** (FORMERLY KNOWN AS REGENCY TRUST LIMITED ("the Company")), which comprise the balance sheet as at 31st March 2024, and the statement of Profit and Loss, and statement of cash flows for the year then ended, and notes to the financial statements, including a summary of significant accounting policies and other explanatory information.

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid financial statements give the information required by the Companies Act, 2013 in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the state of affairs of the Company as at March 31, 2024, and its financial performance, and its cash flows for the year ended on that date.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Emphasis of Matter



The company's is having accumulated losses of Rs.55,027,744/- in Profit & Loss Account as at end of the year. The company have losses in the Profit & Loss Account. As per the management the company is still a going concern entity and it is in process of identifying new plans to improve the performance of the company. Instead of the above factors there is no uncertainty on the company's ability to continue as a going concern. The company has prepared its financial statements on a going concern basis.

Information other than the Financial Statements and Auditors' Report thereon

The Company's management and Board of Directors are responsible for the other information. The other information comprises the information included in the Company's annual report, but does not include the financial statements and our auditors' report thereon.

Our opinion on the financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit, or otherwise appears to be materially misstated.

If, based on the work we have performed on the other information obtained prior to the date of this auditor's report, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Responsibilities of Management and Those Charged with Governance for the Financial Statements

The Company's Board of Directors is responsible for the matters stated in section 134(5) of the Companies Act, 2013 ("the Act") with respect to the preparation of these financial statements that give a true and fair view of the financial position, financial performance, and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the accounting Standards specified under section 133 of the Act. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the



financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the Board of Directors is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the company's financial reporting process.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion.

Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the



financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.

- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Report on Other Legal and Regulatory Requirements

1. As required by the Companies (Auditor's Report) Order, 2020 ("the Order"), issued by the Central Government of India in terms of sub-section (11) of section 143 of the Companies Act, 2013, we give in the "Annexure A" a statement on the matters specified in paragraphs 3 and 4 of the Order, to the extent applicable.
2. As required by Section 143(3) of the Act, we report that:
 - (1) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.
 - (2) In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books.
 - (3) The Balance Sheet, the Statement of Profit and Loss, and the Cash Flow Statement dealt with by this Report are in agreement with the books of account.
 - (4) In our opinion, the aforesaid financial statements comply with the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014.
 - (5) On the basis of the written representations received from the directors as on 31st March, 2024 taken on record by the Board of Directors, none of the directors is disqualified as



on 31st March, 2024 from being appointed as a director in terms of Section 164(2) of the Act.

(6) With respect to the adequacy of the internal financial controls with reference to financial statements of the Company and the operating effectiveness of such controls, the company is exempt from getting an audit opinion on internal financial control.

(7) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:

(a) The Company has disclosed details regarding pending litigations in note 28 of financial statements, which would impact its financial position.

(b) The Company does not have any long-term contracts including derivative contracts for which there were any material foreseeable losses.

(c) There were no amounts which were required to be transferred to the Investor Education and Protection Fund by the Company.

(d) (i) The management has represented that, to the best of it's knowledge and belief, other than as disclosed in the notes to the accounts, no funds have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the company to or in any otherperson(s) or entity(ies), including foreign entities ("Intermediaries"), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall, whether, directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the company ("UltimateBeneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries;

(ii) The management has represented, that, to the best of it's knowledge and belief, other than as disclosed in the notes to the accounts, no funds have been received by the company from any person(s) or entity(ies), including foreign entities ("Funding Parties"), with the understanding, whether recorded in writing or otherwise, that the company shall, whether, directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries; and



(iii) Based on audit procedures which we considered reasonable and appropriate in the circumstances, nothing has come to their notice that has caused them to believe that the representations under sub-clause (i) and (ii) contain any material mis-statement.

(e) The company has not declared or paid any dividend during the year in contravention of the provisions of section 123 of the Companies Act, 2013.

(8) With respect to the matter to be included in the Auditors' Report under Section 197(16) of the Act, in our opinion and according to the information and explanations given to us, the limit prescribed by section 197 for maximum permissible managerial remuneration is not applicable to a private limited company.

For LK Ajmera & Associates
Chartered Accountants
Firm Registration No: FRN 137051W



Lalit Kumar Ajmera
Proprietor
Membership No: 156116
UDIN: 24156116BKAIUA8403
Peer Review No. 014614



Place: Mumbai
Date: 28/05/2024

**ANNEXURE OF REPORT ON CARO, 2022 FORMING INTEGRAL PART OF THE
INDEPENDENT AUDITORS' REPORT FOR THE FINANCIAL YEAR ENDED ON
31/03/2024**

Report as required by the Companies (Auditor's Report) Order, 2020 ("the Order"), issued by the Central Government of India in terms of sub-section (11) of section 143 of the Companies Act, 2013 (Refer to in paragraph 1 under 'Report on Other Legal and Regulatory Requirements' section of our report of even date) With reference to the Annexure A referred to in the Independent Auditors' Report to the members of the Company on the financial statements for the year ended March 31, 2024, we report the following:

(i) (a) (A) The Company has proper records related to full particulars including quantitative details and situation of Property, Plant and Equipment. (B) the company is not having any intangible asset. Therefore, the provisions of Clause (i)(a)(B) of paragraph 3 of the order are not applicable to the company.


(b) In our opinion Property, Plant and Equipment have been physically verified by the management at reasonable intervals. No material discrepancies were noticed on such verification during the year.

(c) According to the information and explanations given to us and the records made available to us, we state that the title deeds of properties are held in the name of the Company.

(d) Details of immovable properties, which are not held in the name of the company, are given below: None

(e) The company has not revalued its Property, Plant and Equipment during the year. Therefore, the provisions of Clause (i)(d) of paragraph 3 of the order are not applicable to the company.

(f) No proceedings have been initiated or are pending against the company for holding any benami property under the Benami Transactions (Prohibition) Act, 1988 (45 of 1988) and rules made thereunder. Therefore, the provisions of Clause (i)(e) of paragraph 3 of the order are not applicable to the company.



(ii) (a) The company had no inventories during the year, therefore, there is no question of conducting any physical verification of inventory at reasonable intervals by the management and the coverage and procedure of such verification by the management is appropriate or not.

(b) During any point of time of the year, the company has not been sanctioned any working capital limits, from banks or financial institutions on the basis of security of current assets. Therefore, the provisions of Clause(ii)(b) of paragraph 3 of the order are not applicable to the company.

(iii) During the year, the company has not made any investments in, provided any guarantee or security or granted any loans or advances in the nature of loans, secured or unsecured, to companies, firms, Limited Liability Partnerships or any other parties. Therefore, the provisions of clause 3(iii) of the said Order are not applicable to the company.

(iv) The company has not made any loans, investments, guarantees and security on which provisions of section 185 and 186 of the Companies Act 2013 are applicable. Therefore, the provisions of clause 3(iv) of the said Order are not applicable to the company.

(v) In our opinion and according to the information and explanations given to us, the Company has not accepted any deposits from public. Therefore, the provisions of Clause (v) of paragraph 3 of the order are not applicable to the Company.

(vi) As explained to us, the Central Government of India has not specified the maintenance of cost records under sub-section (1) of Section 148 of the Act for any of the products of the Company. Therefore, the provisions of Clause (vi) of paragraph 3 of the order are not applicable to the Company.

(vii) (a) The Company is generally regular in depositing undisputed statutory dues including Provident Fund, Employees State Insurance, Income tax, Sales Tax, Wealth tax, Service tax, Duty of Customs, duty of Excise, Value Added Tax, GST, Cess and other statutory dues with the appropriate authorities to the extent applicable to it. There are no undisputed amounts payable in respect of income tax, wealth tax, sales tax, value added tax, duty of customs, duty of excise or cess which have remained outstanding as at March 31, 2024 for a period of more than 6 months from the date they became payable.

(b) According to the information and explanations given to us, there are not any statutory dues referred in sub- clause (a) which have not been deposited on account of any dispute.



(viii) In our opinion and according to the information and explanations given to us, there is no any transaction not recorded in the books of account have been surrendered or disclosed as income during the year in the tax assessments under the Income Tax Act, 1961 (43 of 1961).

(ix) (a) In our opinion and according to the information and explanations given to us, the Company has not defaulted in repayment of any loan or other borrowings or any interest due thereon to any lender.

(b) In our opinion and according to the information and explanations given to us, the company has not been a declared wilful defaulter by any bank or financial institution or other lender.

(c) In our opinion and according to the information and explanations given to us, the loans were applied for the purpose for which the loans were obtained.

(d) In our opinion and according to the information and explanations given to us, there are no funds raised on short term basis which have been utilized for long term purposes.

(e) In our opinion and according to the information and explanations given to us, the company has not taken any funds from any entity or person on account of or to meet the obligations of its subsidiaries, associates or joint ventures.

(f) In our opinion and according to the information and explanations given to us, the company has not raised loans during the year on the pledge of securities held in its subsidiaries, joint ventures or associate companies.

(X) (a) The Company has not raised money by way of initial public offer or further public offer (including debt instruments). Therefore, the provisions of Clause (x) (a) of paragraph 3 of the order are not applicable to the Company.

(b) In our opinion and according to the information and explanations given to us, the company has not made preferential allotment or private placement of shares during the year.

(xi) (a) We have not noticed any case of fraud by the company or any fraud on the Company by its officers or employees during the year. The management has also not reported any case of fraud during the year.

(b) During the year no report under sub-section (12) of section 143 of the Companies Act has been filed by the auditors in Form ADT-4 as prescribed under rule 13 of Companies (Audit and Auditors) Rules, 2014 with the Central Government.

(c) As auditor, we did not receive any whistle-blower complaint during the year.



(Xii) The company is not a Nidhi Company. Therefore, the provisions of Clause (xii) of paragraph 3 of the order are not applicable to the Company.

(Xiii) As per the information and explanations received to us all transactions with the related parties are in compliance with sections 177 and 188 of Companies Act where applicable, and the details have been disclosed in the financial statements, etc., as required by the applicable accounting standards. Identification of related parties were made and provided by the management of the company.

(Xiv) The company is not covered by section 138 of the Companies Act, 2013, related to appointment of internal auditor of the company. Therefore, the company is not required to appoint any internal auditor. Therefore, the provisions of Clause (xiv) of paragraph 3 of the order are not applicable to the Company.

(Xv) The Company has not entered into any non-cash transactions with directors or persons connected with him for the year under review. Therefore, the provisions of Clause (xv) of paragraph 3 of the order are not applicable to the Company.

(Xvi) (a) The Company is not required to be registered under section 45-IA of the Reserve Bank of India Act, 1934.

(b) The company has not conducted any Non-Banking Financial or Housing Finance activities during the year.

(c) The company is not a Core Investment Company (CIC) as defined in the regulations made by the Reserve Bank of India (d) As per the information and explanations received, the group does not have any CIC as part of the group.

(Xvii) The company has incurred cash profit of Rs.6,93,192/- in current financial year and of cash loss Rs.45,19,301/- in the immediately preceding financial year.

(Xviii) There has been no resignation of the previous statutory auditors during the year.

(Xix) On the basis of the financial ratios, ageing and expected dates of realization of financial assets and payment of financial liabilities, other information accompanying the financial statements, the auditor's knowledge of the Board of Directors and management plans, we are



of the opinion that no material uncertainty exists as on the date of the audit report that company is capable of meeting its liabilities existing at the date of balance sheet as and when they fall due within a period of one year from the balance sheet date.

(XX) There is no liability of the company under the provisions of section 135 of the Companies Act, relating to Corporate Social Responsibility. Therefore, the provisions of Clause (xx) of paragraph 3 of the order are not applicable to the Company.

(XXi) The company has not made investments in subsidiary company. Therefore, the company does not require to prepare consolidated financial statement. Therefore, the provisions of Clause (xxi) of paragraph 3 of the order are not applicable to the Company.

For LK Ajmera & Associates
Chartered Accountants
Firm Registration No: FRN 137051W



Lalit Kumar Ajmera
Proprietor
Membership No: 156116
UDIN: 24156116BKAIUA8403
Peer Review No.



Place: Mumbai
Date: 28/05/2024

CHECKPOINT TRENDS LIMITED
(FORMERLY KNOWN AS RUBRA MEDICAMENTS LIMITED)
BALANCE SHEET AS AT 31ST MARCH 2024

Rs. In Thousands

	Particulars	Note	As at 31.03.2024	As at 31.03.2023
			(Rupees)	(Rupees)
	1	2	3	4
1	EQUITY AND LIABILITIES			
	Equity			
	(a) Equity Share capital	2	54,683.00	54,683.00
	(b) Other Equity	3	(49,355.42)	(49,657.51)
	Total Equity		5,327.58	5,025.49
	LIABILITIES			
2	Non- current liabilities			4.13
	Deferred tax liabilities (net)		-	4.13
	Total Non-Current Liabilities			4.13
3	Current liabilities			
	Short Term Borrowings		-	1,473.65
	Trade payables		11.86	11.87
	Provisions	4	3,995.41	78.19
	Total Current Liabilities		4,007.27	1,563.71
	Total Liabilities		4,007.27	1,567.84
	Total equity and Liabilities		9,334.85	6,593.33
	ASSETS			
1	Non-current asset			
	Property, Plant and Equipment	5	675.44	606.59
	Deferred Tax Assets (Net)		73.48	-
	Total Non-Current Assets		748.92	606.59
2	Current Assets			
	Trade Receivable		7,072.50	4,302.50
	Cash and cash equivalents		127.42	222.97
	Bank balances other than (iii) above		10.01	77.48
	Loans	6	1,150.00	1,150.00
	Other current assets	7	226.00	233.80
	Total Current Assets		8,585.93	5,986.75
	Total Assets		9,334.85	6,593.33
			-	(0)
	Overview and Significant Accounting Policies	1		
	The notes are an integral part of Financial Statements	12		

As per our Report of even date.

For LK Ajmera & Associates

Chartered Accountants

FRN : 137051W

Lalit Kumar Ajmera

Proprietor

Membership No.156116

Mumbai

Date: May 25, 2024

UDIN - 24156116BKAITW2989



For and on behalf of Board of Directors

Checkpoint Trends Limited

(Formerly known as Rubra Medicaments Limited)

Abha Kapoor

Gopal Kumar Sahu

Abha Kapoor

Gopal Kumar Sahu

Director

DIN : 02799429

Director

DIN : 08478039

CHECKPOINT TRENDS LIMITED
(FORMERLY KNOWN AS RUBRA MEDICAMENTS LIMITED)
STATEMENT OF PROFIT AND LOSS FOR THE YEAR ENDED 31ST MARCH, 2024

Particulars	Note No	Rs. In Thousands	
		As At 31.03.2024 (Rupees)	As At 31.03.2023 (Rupees)
INCOME			
Revenue from operations		11,300.00	11,601.50
Other Income		9.35	16.29
Total		11,309.35	11,617.79
EXPENDITURE			
Purchase of Stock in Trade		-	-
Employee Benefit Expenses	8	4,995.77	3,536.55
Finance Cost	9	2.31	0.66
Depreciation	5	70.29	29.02
Other expenses	10	6,016.51	8,858.26
Total		11,084.87	12,424.49
Profit / (Loss) before exceptional and extraordinary items and tax		224.48	(806.70)
Exceptional Items		-	-
Profit before extraordinary items and tax		224.48	(806.70)
Extraordinary Items		-	-
Profit before tax		224.48	(806.70)
Tax expense:			
Current tax expense relating to current year		-	(21.19)
Current tax expense relating to prior years		-	-
Deferred tax		(77.62)	-
Profit(Loss) for the year after taxation		302.09	(785.51)
Earning per equity share:			
(1) Basic	11	0.06	-0.14
(2) Diluted	11	0.06	-0.14
Overview and Significant Accounting Policies	1		
The notes are an integral part of Financial Statements	12		

As per our Report of even date.

For LK Ajmera & Associates
Chartered Accountants
FRN : 137051W

Lalit Kumar Ajmera

Lalit Kumar Ajmera
Proprietor
Membership No.156116
Mumbai
Date : May 25, 2024



For and on behalf of Board of Directors
Checkpoint Trends Limited
(Formerly known as Rubra Medicaments Limited)
Abha Kapoor Gopal Kumar Sahu

Abha Kapoor

Director
DIN: 02799429

Gopal Kumar Sahu

Director
DIN: 08478039

UDIN-24156116BKAITW2989

CHECKPOINT TRENDS LIMITED

Summary of significant accounting policies and other explanatory information to the financial statements as at and for the year ended 31 March 2024

1

Significant Accounting Policies

1.1 Basis of preparation of financial statements

The financial statements are prepared on going concern basis in accordance with Generally Accepted Accounting Principles in India (GAAP) and comply in all material respects with the Accounting Standards specified under section 133 of the Companies Act, 2013, read with Rule 7 of the Companies (Accounts) Rules, 2014, and Companies (Accounting Standards) Amendment Rules, 2016 and the relevant provisions of the Companies Act, 2013.

1.2 Historical Cost Convention

The financial statements have been prepared on an accrual basis and under the historical cost convention. The accounting policies adopted in the preparation of financial statements are consistent with those of previous year.

1.3 Use of estimates

The preparation of financial statements requires the management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent liabilities as at the date of the financial statements and the reported amount of revenue and expenses for the year. Actual results could differ from these estimates. Any revision to such accounting estimates is recognized prospectively in current and future periods.

1.4 Property, plant and equipment

All items of PPE are stated at cost less depreciation and impairment, if any. Historical cost includes expenditure that is directly attributable to the acquisition of the items. Cost includes its purchase price including non-refundable taxes and duties, directly attributable costs of bringing the asset to its present location and condition and initial estimate of costs of dismantling and removing the item and restoring the site on which it is located.

Subsequent costs are included in the carrying amount of PPE or recognised as a separate PPE, as appropriate, only when it is probable that future economic benefits associated with the item will flow to the Company and the cost of the item can be measured reliably. The carrying amount of any component accounted for as a separate asset is derecognised when replaced. All other repairs and maintenance are charged to the Statement of Profit and Loss during the reporting period in which they are incurred.

1.5 Depreciation

The Company depreciates its PPE over the useful life in the manner prescribed under Part C of Schedule II to the Act. Depreciation commences when the assets are ready for their intended use and is computed on pro-rata basis from the date of installation/ acquisition till the date of sale/ disposal. Management believes that useful life of assets are same as those prescribed in Schedule II to the Act.

1.6 Inventories

Inventories are valued at lower of cost or estimated net realisable value. As on 31st March Company does not have any inventory in its books.

1.7 Revenue recognition

Revenue is recognised to the extent that it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured, regardless of when the payment is being made. Revenue is measured at the fair value of the consideration received or receivable net of discounts, returns and rebates taking into account contractually defined terms and excluding taxes or duties collected on behalf of the government.

a) Sales are recognised when substantial risk and rewards of ownership are transferred to customer as per the terms of contract. No revenue is recognised if there are significant uncertainties regarding recovery of the amount due, associated costs or the possible return of goods

b) Interest income is accrued on a time proportion basis, by reference to the principal outstanding and the applicable effective interest rate.

c) Dividend income from investments is recognised when the shareholder's rights to receive payment have been established.

1.8 Investments

a) Company does not have any long term investment as on 31st March 2024.

b) Current investments are stated at lower of cost and fair market value determined on an individual investment basis. Long-term investments are stated at cost less provision for diminution other than temporary in the value of such investments.

1.9 Borrowing costs

Borrowing costs are interest and other costs that the Company incurs in connection with the borrowing of funds and is measured with reference to the effective interest rate applicable to the respective borrowing.

1.10 Employee benefits

Company does not provided any Employee benefit provision in financials as company does not cross the required limit of no of Employees.

(ii) Post-employment Obligations

(i) Short-term Obligations

1.11 Accounting for taxes on Income

a) Current tax is determined as the amount of tax payable in respect of taxable income for the year as per the provisions of the Income Tax Act, 1961.

b) Deferred tax is recognized, subject to consideration of prudence, on timing difference, being the difference between taxable incomes and accounting income that originate in one period and are capable of reversal in one or more subsequent periods and measured using relevant enacted tax rates.

1.12 Operating lease

A. Where Co is lessee

Lease of assets under which all the risk and rewards of ownership are effectively retained by the lessor are classified as operating leases. Lease payments under operating leases are recognized as an expense on accrual basis in accordance with the respective lease agreements.

B. Where Co is lessor



Leases in which the Company does not transfer substantially all the risks and rewards of ownership of an asset are classified as operating leases. Rental income from operating lease is recognised on a straight line basis over the term of the relevant lease.

1.13 Foreign currency transactions

Transactions in foreign currencies are recognised at the prevailing exchange rates on the transaction dates. Realised gains and losses on settlement of foreign currency transactions are recognised in the Statement of Profit and Loss.

Monetary foreign currency assets and liabilities at the year-end are translated at the year-end exchange rates and the resultant exchange differences are recognised in the Statement of Profit and Loss.

1.14 Earnings per share

Basic earnings per share are computed by dividing the profit / (loss) after tax by the weighted average number of equity shares outstanding during the year. The weighted average number of equity shares outstanding during the year is adjusted for the events for bonus issue, bonus element in a rights issue to existing shareholders, share split and reverse share split (consolidation of shares). Diluted earnings per share is computed by dividing the profit / (loss) after tax as adjusted for dividend, interest and other charges to expense or income (net off any attributable taxes) relating to the dilutive potential equity shares, by the weighted average number of equity shares considered for deriving basic earnings per share and the weighted average number of equity shares which could have been issued on conversion of all dilutive potential equity shares.

1.15 Provisions

A provision is recognised when the Company has a present obligation (legal or constructive) as a result of past event, it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation. These estimates are reviewed at each reporting date and adjusted to reflect the current best estimates.

1.16 Contingent Liabilities and Contingent Assets

A contingent liability is a possible obligation that arises from past events whose existence will be confirmed by the occurrence or non-occurrence of one or more uncertain future events beyond the control of the Company or a present obligation that is not recognised because it is not probable that an outflow of resources will be required to settle the obligation. A contingent liability also arises in extremely rare cases, where there is a liability that cannot be recognised because it cannot be measured reliably. The Company does not recognize a contingent liability but discloses its existence in the financial statements unless the probability of outflow of resources is remote.

1.17 Impairment of property, plant and equipment

At each balance sheet date, the Company reviews the carrying amount of assets to determine whether there is an indication that those assets have suffered impairment loss. If any such indication exists, the recoverable amount of assets is estimated in order to determine the extent of impairment loss. The recoverable amount is higher of the net selling price and value in use, determined by discounting the estimated future cash flows expected from the continuing use of the asset to their present value.

1.18 Current and Non-current Classification

All assets and liabilities have been classified as current and non-current as per the Company's normal operating cycle (Twelve months) and other criteria set out in Schedule III to the Act.



Notes forming part of the financial statements

1.19 Ratios

Particulars	Numerator	2022-23		2023-24		Variance in %
		Values	Ratio	Values	Ratio	
a) Current ratio	Current Assets	5,987	3.82	8,586	2.14	(0.02)
	Current Liabilities	1,568		4,007		
	Debt	-		-		
b) Debt-Equity ratio	Shareholders Equity	5,025	-	5,328	0.00	-
	EBIT		Not Applicable			
c) Debt service coverage ratio	Interest					
	Net profit after tax	(807)	(0.07)	224	0.02	0.00
d) Net profit ratio *	Sales	11,602		11,300		
	Net profit for equity shareholder	(786)	(0.14)	302	0.06	0.00
	No of shareholder	5,468		5,468		
f) Trade receivables turnover ratio	CR. Sales	11,602	2.70	11,300	1.60	(0.01)
	Average Debtors	4,303		7,073		
	CR. Purchase	-		-		
g) Trade payables turnover ratio	Average Creditors	12		12		
	Sales	11,602		11,300		
	Average Working Capital	4,423	2.62	4,579	2.47	(0.00)

CHECKPOINT TRENDS LIMITED

(FORMERLY KNOWN AS RUBRA MEDICAMENTS LIMITED)

NOTES FORMING PART OF FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2024

Rs. In Thousands

PARTICULARS	AS AT			
	31.03.2024 (Rupees)	31.03.2023 (Rupees)		
2 SHARE CAPITAL				
Authorised				
82,00,000 Equity Shares of Rs.10 each (Previous Year 82,00,000 Equity Shares of Rs.10 each)	82,000.00	82,000.00		
TOTAL	82,000.00	82,000.00		
Issued, Subscribed & Paid-up				
54,68,300 Equity Shares of Rs.10 each (Previous Year 54,68,300 Equity Shares of Rs.10 each)	54,683.00	54,683.00		
TOTAL	54,683.00	54,683.00		
2.1 Reconciliation of number and amount of shares				
Particulars	As at March 31,2024		As at March 31,2023	
	Number	(Rupees)	Number	(Rupees)
Issued, Subscribed & Fully Paid up				
Equity Shares of 10/- each				
Balance as at the beginning of the year	5,468.30	54,683.00	5,468.30	54,683.00
Add : Issued during the year	-	-	-	-
Less : Buy Back of Shares	-	-	-	-
Balance as at the end of the year	5,468.30	54,683.00	5,468.30	54,683.00

2.2 Details of shares held by shareholders holding more than 5% of the aggregate shares in the company

Particulars	As at March 31,2024		As at March 31,2023	
	No. of shares held	% of Holding	No. of shares held	% of Holding
Shriram Credit Company Limited	363.60	6.65%	363.60	6.65%
Taradevi Toshniwal	878.78	16.07%	878.78	16.07%
Religare Finvest Limited	322.00	5.89%	322.00	5.89%

2.3 Terms/Rights of Shareholders

The Company has only one class of shares referred to as equity shares having a par value of Rs.10/- per share. Each holder of equity share is entitled to one vote per share. The Company declares and pays dividends in Indian rupees. The dividend proposed by the Board of Directors is subject to the approval of the shareholders in ensuing Annual General Meeting. In the event of the liquidation of the Company, the holder of equity share will be entitled to receive any of the remaining assets of the Company after distribution of all preferential amounts. The distribution will be in proportion of the number of the equity shares held by the equity shareholders



CHECKPOINT TRENDS LIMITED
(FORMERLY KNOWN AS RUBRA MEDICAMENTS LIMITED)

NOTES FORMING PART OF FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2024

3 RESERVES & SURPLUS

Rs. In Thousands

PARTICULARS	AS AT	AS AT
	31.03.2024 (Rupees)	31.03.2023 (Rupees)
State Subsidy	355.74	355.74
<u>Surplus</u>		
Opening Balance		
Add : Net profit after tax for the year	(50,013.25)	(52,602.75)
Less : Share Application Money	302.09	(785.51)
TOTAL	(49,355.42)	(49,657.51)

4 SHORT TERM PROVISIONS

PARTICULARS	AS AT	AS AT
	31.03.2024 (Rupees)	31.03.2023 (Rupees)
Audit Fees Payable	98.00	-
Duties & Taxes	339.65	-
Salary & Wages Payable	3,475.00	50.00
TDS on Prof. Fees Payable	34.22	9.50
TDS on Labour Charges Payable	48.54	18.69
TOTAL	3,995.41	78.19

6 LONG TERM LOANS & ADVANCES

PARTICULARS	AS AT	AS AT
	31.03.2024 (Rupees)	31.03.2023 (Rupees)
Advances for Value Received	1,150.00	1,150.00
TOTAL	1,150.00	1,150.00

7 OTHER CURRENT ASSETS

PARTICULARS	AS AT	AS AT
	31.03.2024 (Rupees)	31.03.2023 (Rupees)
Deposits/TDS	226.00	233.80
TOTAL	226.00	233.80



CHECKPOINT TRENDS LIMITED
(FORMERLY KNOWN AS RUBRA MEDICAMENTS LIMITED)

NOTES FORMING PART OF FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2024

8 EMPLOYEE BENEFIT EXPENSES

Rs. In Thousands

PARTICULARS	AS AT 31.03.2024 (Rupees)	AS AT 31.03.2023 (Rupees)
Salary, Bonus & Other allowances	4,995.77	3,536.55
TOTAL	4,995.77	3,536.55

9 FINANCE COST

PARTICULARS	AS AT 31.03.2024 (Rupees)	AS AT 31.03.2023 (Rupees)
Bank Charges	2.31	0.66
TOTAL	2.31	0.66

10 OTHER EXPENSES

PARTICULARS	AS AT 31.03.2024 (Rupees)	AS AT 31.03.2023 (Rupees)
Advertisement Expenses	30.11	27.29
Audit Fees	150.00	55.00
Event Expenses	2,620.70	4,802.72
Hotel Expenses	1,737.46	-
Legal & Professional Fees	80.00	-
Labour Charges	131.70	1,868.69
Listing Fee	334.75	300.00
Office Expenses	173.06	27.87
Raw Material Charges	-	35.54
ROC Filing Fees	50.00	100.00
Service Charges/Custodian Fee	42.17	42.15
Share Transfer Agent	62.20	69.74
Telephone Charges	-	116.10
Travelling Expenses	446.58	1,405.35
Website Renewal Charges	7.80	7.80
Wedding Expenses-Photography	150.00	-
TOTAL	6,016.51	8,858.26



CHECKPOINT TRENDS LIMITED
(FORMERLY KNOWN AS RUBRA MEDICAMENTS LIMITED)

NOTES FORMING PART OF FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2024

11 EARNING PER SHARE

Rs. in Thousands

PARTICULARS	AS AT	AS AT
	31.03.2024 (Rupees)	31.03.2023 (Rupees)
Net Profit / (Loss) after current and deferred tax	302.09	(785.51)
No. of Shares	5,468.30	5,468.30
EPS (Rs.) - Basic and Diluted	0.06	-0.14

12 OTHER NOTES

12.1 Segment Reporting-

The Company operates in one business segment of trading. As such, there are no separate reportable business segments as per Accounting Standard, AS-17 Segment Reporting, as prescribed by the Rules.

12.2 Related party Disclosure

As per Accounting Standard (AS18) on 'Related Party Disclosure', the related parties are as under :
During the current year, following transaction has been carried out with the related parties.

Loan from Director Nil

12.3 Previous year figures have been regrouped, and reclassified wherever considered necessary to conform to current year's classification

As per our Report of even date.

For LK Ajmera & Associates
Chartered Accountants
FRN: 137051W



Lalit Kumar Ajmera
Proprietor

Membership No.156116
Mumbai
Date : May 25, 2024

For and on behalf of Board of Directors
Checkpoint Trends Limited
(Formerly known as Rubra Medicaments Limited)
Abha Kapoor Gopal Kumar Sahu


Director
DIN : 02799429


Director
DIN : 08478039

CHECKPOINT TRENDS LIMITED**(FORMERLY KNOWN AS RUBRA MEDICAMENTS LIMITED)****NOTES FORMING PART OF FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH, 2024****SCHEDULES TO ACCOUNTS AS AT 31st March, 2024.****Rs. in Thousands****Schedule 5****FIXED ASSETS**

PARTICULARS	Gross Block 01.04.23	Additions	Deductions	Total	Depreciation			Net Block as on 31.03.24	Net Block as on 31.03.23
					Upto 01.04.23	For The Year Year	Total as on 31.03.24		
Office Equipments	106.75	139.14		245.89	27.13	15.36	42.49	203.40	79.62
Furniture & Fixture	577.00	-	-	577.00	50.03	54.93	104.96	472.04	528.97
TOTAL (Rs.)	683.75	139.14	-	822.89	77.16	70.29	147.45	675.44	606.59

CHECKPOINT TRENDS LIMITED**FORMERLY KNOWN AS RUBRA MEDICAMENTS LIMITED****NOTES FORMING PART OF FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH, 2023****SCHEDULES TO ACCOUNTS AS AT 31st March, 2023.****Rs. in Thousands****Schedule 5****FIXED ASSETS**

PARTICULARS	Gross Block 01.04.22	Additions	Deductions	Total	Depreciation			Net Block as on 31.03.23	Net Block as on 31.03.22
					Upto 01.04.22	For The Year Year	Total as on 31.03.23		
Office Equipments	66.07	40.68		106.75	18.93	8.20	27.13	79.62	47.15
Furniture & Fixture	102.00	475.00	-	577.00	29.22	20.82	50.03	528.97	72.78
TOTAL (Rs.)	168.07	515.68	-	683.75	48.14	29.02	77.16	606.59	119.93



CHECKPOINT TRENDS LIMITED
(FORMERLY KNOWN AS RUBRA MEDICAMENTS LIMITED)
CASH FLOW STATEMENT FOR THE YEAR ENDED MARCH, 2024


Rs. In Thousands

	Particulars	March 31, 2024	March 31, 2023
		RUPEES	RUPEES
A	<u>Cash Flow From Operating Activities</u>		
	Net Profit before tax and Extraordinary Items	224.48	(806.70)
	Adjustment for :		
	Depreciation	70.29	29.02
	Operating Profit before working Capital Changes	294.76	(777.68)
	Adjustment for Capital Changes:		
	Increase/Decrease in Current Liabilities & Provisions	2,443.57	(1,096.65)
	Increase/Decrease in Trade Payables	(0.01)	6.09
	Increase/Decrease in Fixed Assets	(139.14)	(515.68)
	Increase/Decrease in Cash Loans and advances	7.80	139.95
	Increase/Decrease in Trade Receivables	(2,770.00)	2,360.00
	Cash Generated From Operations	(163.02)	116.03
	Income Tax / Deferred Tax Paid	-	(21.19)
	Extraordinary items	-	-
	<u>Net cash from Operating Activities</u>	(163.02)	137.22
B	<u>Net Cash From Investing Activities</u>	-	-
C	<u>Net Cash Flow From Financing Activities</u>	-	-
	Net Increase (Decrease) in cash & cash equivalents (A+B+C)	(163.02)	137.22
	Opening Balance of Cash & Cash Equivalents	300.45	163.22
	Closing Balance of Cash & Cash Equivalents	137.43	300.45

As per our Report of even date.

(0)

For LK Ajmera & Associates
Chartered Accountants
 FRN: 137051


 Lalit Kumar Ajmera
 Proprietor
 Membership No.156116
 Mumbai
 Date: May 25, 2024




For and on behalf of Board of Directors
Checkpoint Trends Limited
 (Formerly known as Rubra Medicaments Limited)

Abha Kapoor

Gopal Kumar Sahu





Director
 DIN: 02799429

Director
 DIN: 08478039